Skip to content

Evaluation of Direct Transfer to Angiography Suite vs. Computed Tomography Suite in Endovascular Treatment: Randomized Clinical Trial (ANGIOCAT)

Evaluation of Direct Transfer to Angiography Suite vs. Computed Tomography Suite in Endovascular Treatment: Randomized Clinical Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04001738
Acronym
ANGIOCAT
Enrollment
174
Registered
2019-06-28
Start date
2018-08-14
Completion date
2020-11-07
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Acute

Keywords

Endovascular treatment, Large Vessel Occlusion

Brief summary

To evaluate the hypothesis that an ultra-fast triage with one-stop in angiography suite based on cone-beam CT compared to traditional protocol offers a better outcome in the distribution of the modified Rankin Scale scores at 90 days in acute ischemic stroke patients with suspected large vessel occlusion (LVO) within 6 hours from symptoms onset.

Detailed description

Prospective, randomized, open, treatment-blinded trial of acute stroke patients with suspected large vessel occlusion within 6 hours from symptoms onset in which two strategies will be compared: Direct Transfer to Angiography Suite (DTAS) vs. Computed Tomography Suite (DTCT). The study will be unicentric however there is the possibility of incorporating new stroke centers with previous experience of at least 50 DTAS cases. The RACE scale (Rapid Arterial oCclusion Evaluation) will be used as a prehospital screening tool to identify acute stroke patients with suspicion of LVO. Once prenotifying the imminent arrival and the verified inclusion and exclusion criteria by the Neurologist at arrival, the patient will be randomized by an app in one of both study protocols. Subjects will be followed up to 90 days post-randomization.

Interventions

OTHERDirect Transfer to Angio Suite

Patient will be direct transferred to angiography suite where EVT team will be waiting for it.

Sponsors

Hospital Vall d'Hebron
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Large vessel occlusion suspected acute stroke codes (RACE\>4) within 6 hours from stroke onset which are prenotified from emergency medical system. * Confirmed NIHSS\>10 at arrival. * Good pre-stroke functional status (mRS≤2) * Angiography suite available. * Endovascular treatment team available (Neurologist, Interventionist, anesthesiologist, Nursery, Technicians…)

Exclusion criteria

* Hemodynamically unstable patients who requires of advanced vital support. * Patients with an advanced disease that conditions a life expectancy lower than 6 months. * Participation in other clinical trial with a drug or device which could influence in the outcome. * Patients with neurological or psychiatric disease that could confound future evaluations. * Lack of disponibility for 90 days tracing.

Design outcomes

Primary

MeasureTime frameDescription
Clinical outcome measurde by modified Rankin Scale score (shift analysis)90 daysModified Rankin Scale score in ischemic stroke patients with large vessel occlusion as evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment. Modified Rankin Scale measures functional status with a range from 0 (asymptomatic) to 6 (dead).
Rate of patients with treatment associated complications.72 hoursLack of treatment associated complications, mainly hemorrhagic transformation.

Secondary

MeasureTime frameDescription
Delay of inhospital times8 hoursTime from door to groin puncture
Rate of dramatic improvement24 hours10 NIHSS points drop or NIHSS \<2
Rate of good functional outcome90 daysModified Rankin Scale score ≤2
Rate of patients treated by endovascular treatment8 hours

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026